News & Updates
Filter by Specialty:

Breastfeeding protects women against postpartum CVD
Women who breastfeed, especially those with prior gestational diabetes mellitus (GDM), appear to have greater protection against long-term atherosclerotic cardiovascular disease (ASCVD), suggest the results of a study presented at SMFM 2025.
Breastfeeding protects women against postpartum CVD
20 Feb 2025
Postpartum diuretics use eases persistent hypertension
The postpartum use of diuretics can reduce persistent hypertension in women with hypertensive disorders of pregnancy (HDP), according to the results of a systematic review and meta-analysis presented at SMFM 2025.
Postpartum diuretics use eases persistent hypertension
20 Feb 2025
Probiotics may be a promising treatment for depression
Probiotics may be efficacious either as an adjunct to antidepressants or as a standalone treatment for major depressive disorder (MDD), according to results of a meta-analysis and network systematic review.
Probiotics may be a promising treatment for depression
20 Feb 2025
SGLT-2is, GLP-1RAs cut risk of COPD flare-ups
In adults with type 2 diabetes and active chronic obstructive pulmonary disease (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) may also reduce the risk of COPD exacerbations, according to a study.
SGLT-2is, GLP-1RAs cut risk of COPD flare-ups
19 Feb 2025
Infliximab trumps other biologics as maintenance drug in CD
Among the many biologics used to treat adults with moderate-to-severe Crohn’s disease (CD), infliximab subcutaneous (SC) 120 mg every 2 weeks (Q2W) demonstrates the highest efficacy in clinical remission during maintenance treatment of 52 to 64 weeks’ duration, according to the results of a recent study presented at CCC 2025.